Literature DB >> 11971190

Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain.

Hitoshi Kiyoi1, Ryuzo Ohno, Ryuzo Ueda, Hidehiko Saito, Tomoki Naoe.   

Abstract

Internal tandem duplication (ITD) of the juxtamembrane (JM) domain of FLT3 is the most frequent mutation in human acute myeloid leukemia, and is significantly associated with leukocytosis and a poor prognosis. Previously we reported that FLT3 with ITD (FLT3/ITD) formed a homodimer and was autophosphorylated on tyrosine residues, while the mechanism remains unclear. In this study, we elucidated the role of the JM domain in FLT3 activation. Mutant FLT3 with not only ITD but also an elongating or shortening JM domain transformed murine IL3-dependent myeloid progenitor cell line 32D regardless of the tyrosine residues in the JM domain. These mutant FLT3s were constitutively tyrosine phosphorylated and activated signal-transduction molecules such as SHC, MAP kinase and STAT5a. Notably, co-transfection of the truncated FLT3/ITD lacking kinase and C-terminal domains with the wild type (Wt)-FLT3 into 32D cells resulted in the autonomous proliferation. In these cells, truncated FLT3/ITD generated a hetero-complex with Wt-FLT3 and Wt-FLT3 was constitutively tyrosine phosphorylated. These findings indicate that the FLT3 JM domain plays an important role in receptor activation, and that the length-mutated JM domain induces ligand-independent receptor activation but also activates Wt-FLT3 in a trans-manner.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11971190     DOI: 10.1038/sj.onc.1205332

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  86 in total

1.  Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.

Authors:  Jennifer L Rocnik; Rachel Okabe; Jin-Chen Yu; Benjamin H Lee; Neill Giese; David P Schenkein; D Gary Gilliland
Journal:  Blood       Date:  2006-04-20       Impact factor: 22.113

Review 2.  Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation.

Authors:  Hitoshi Kiyoi; Tomoki Naoe
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

Review 3.  FLT3 antibody-based therapeutics for leukemia therapy.

Authors:  Yiwen Li; Zhenping Zhu
Journal:  Int J Hematol       Date:  2005-08       Impact factor: 2.490

4.  FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics.

Authors:  Lei Wang; Wei-lai Xu; Hai-tao Meng; Wen-bin Qian; Wen-yuan Mai; Hong-yan Tong; Li-ping Mao; Yin Tong; Jie-jing Qian; Yin-jun Lou; Zhi-mei Chen; Yun-gui Wang; Jie Jin
Journal:  J Zhejiang Univ Sci B       Date:  2010-10       Impact factor: 3.066

Review 5.  Recent advances and novel agents for FLT3 mutated acute myeloid leukemia.

Authors:  Rahul Pawar; Omar Preet Singh Bali; Bharat Kumar Malhotra; Gurpreet Lamba
Journal:  Stem Cell Investig       Date:  2014-03-20

6.  Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia.

Authors:  Derek L Stirewalt; Kenneth J Kopecky; Soheil Meshinchi; Julia H Engel; Era L Pogosova-Agadjanyan; Jeremy Linsley; Marilyn L Slovak; Cheryl L Willman; Jerald P Radich
Journal:  Blood       Date:  2005-12-20       Impact factor: 22.113

7.  Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis.

Authors:  Anindya Chatterjee; Joydeep Ghosh; Baskar Ramdas; Raghuveer Singh Mali; Holly Martin; Michihiro Kobayashi; Sasidhar Vemula; Victor H Canela; Emily R Waskow; Valeria Visconte; Ramon V Tiu; Catherine C Smith; Neil Shah; Kevin D Bunting; H Scott Boswell; Yan Liu; Rebecca J Chan; Reuben Kapur
Journal:  Cell Rep       Date:  2014-11-13       Impact factor: 9.423

8.  Rare FLT3 deletion mutants may provide additional treatment options to patients with AML: an approach to individualized medicine.

Authors:  N Chatain; R C Perera; G Rossetti; J Rossa; P Carloni; M Schemionek; T Haferlach; T H Brümmendorf; S Schnittger; S Koschmieder
Journal:  Leukemia       Date:  2015-05-27       Impact factor: 11.528

Review 9.  Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.

Authors:  Keith Pratz; Mark Levis
Journal:  Leuk Lymphoma       Date:  2008-05

10.  A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity.

Authors:  Sophia Hu; Masumi Ueda; Lindsay Stetson; James Ignatz-Hoover; Stephen Moreton; Amit Chakrabarti; Zhiqiang Xia; Goutam Karan; Marcos de Lima; Mukesh K Agrawal; David N Wald
Journal:  Mol Cancer Ther       Date:  2016-05-09       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.